drug
(olodaterol hydrochloride + tiotropium bromide)
Marketedupdated 3mo agoby Boehringer Ingelheim Corp
Approvedcommunity read0 votes
indications
investigational
COPD
all catalysts(0)
nothing on the calendar yet
Trials studying (olodaterol hydrochloride + tiotropium bromide)
- —A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol
- —A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 19, 2027
178 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Sep 13, 2028patentUS 7837235*PED2.1y
- Apr 10, 2027patentUS 7396341*PED259d
- Jan 19, 2027compositionUS 7727984178d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 30m ago
Found something off?
comments(0)
5-min edit window · permanent after that